23.21USD-0.77%Mkt Cap: 2.28B USDP/E: —Last update: 2026-05-26
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in N…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
106.49BDKKP/E 20.5
66.47BUSDP/E 15.5
46.51BEURP/E 30.5
43.17BEURP/E 35.9
39.41BUSDP/E 74.0
32.84BUSD—
31.18BSEKP/E 46.1
Indicators:|
Key Statistics
Company
Market Cap2.28B USD
Enterprise Value3.12B USD
Revenue (TTM)670.00M USD
Gross Profit564.00M USD
Net Income (TTM)-575.00M USD
Revenue/Share6.722 USD
Last Price23.21 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees1.4K
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)24.56
PEG—
EV/EBITDA-6.28
EV/Revenue4.66
P/S3.49
P/B-28.57
EPS (TTM)-6.10
EPS (Forward)0.97
52W Range
18.2920% of range42.37
52W High42.37 USD
52W Low18.29 USD
Profitability
Gross Margin83.80%
Oper. Margin-102.21%
EBITDA Margin-74.18%
Profit Margin-85.44%
ROE718.75%
ROA-37.53%
Growth
Revenue Growth-2.20%
Earnings Growth—
Cash Flow & Leverage
Operating CF-466.00M USD
CapEx (TTM)21.00M USD
FCF Margin-32.70%
FCF Yield-9.60%
Net Debt787.00M USD
Net Debt/EBITDA-1.58
Balance Sheet
Debt/Equity-0.45
Current Ratio2.02
Quick Ratio1.65
Book Value/Sh-0.8300 USD
Cash/Share4.206 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.5 (Strong Buy)
Target (Mean)51.42 USD
Target Range25.00 USD – 84.00 USD
# Analysts19
Ownership
Shares Out.98.49M
Float94.63M
Insiders3.46%
Institutions104.15%
Short Interest
Short Ratio7.5d
Short % Float14.38%
Short % Out.13.90%
Shares Short13.67M
Short (prev mo.)11.41M
Technical
SMA 5023.30 (-0.4%)
SMA 20027.56 (-15.8%)
Beta0.39
S&P 52W Chg28.31%
Avg Vol (30d)1.63M
Avg Vol (10d)1.52M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—